Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773270 | 1.00 | KDM4E (0.40) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3785173 | 0.92 | KDM4E (0.39) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3785172 | 0.92 | KDM4E (0.39) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3778109 | 0.91 | KDM4E (0.40) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3778110 | 0.91 | KDM4E (0.40) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3772762 | 0.89 | KDM4E (0.40) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3772760 | 0.89 | KDM4E (0.40) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL31031262 | 0.88 | TRPV1 (0.36) | KDM4EALDH1A1TRPV1MCHR1HPGD | |
| SCHEMBL3770778 | 0.84 | RAB9A (0.40) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3770780 | 0.84 | RAB9A (0.40) | KDM4EALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106660949-B | Chiral resolution method of N- [4- (1-aminoethyl) -phenyl ] -sulfamide derivative | 株式会社爱茉莉太平洋 | 2020-11-13 | — | — | CN | claimed |
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | AMOREPACIFIC CORPORATION (KR) | 2019-11-19 | — | — | US | claimed |
| EP-3162793-B1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORP (KR) | 2019-04-10 | — | — | EP | claimed |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2017-11-30 | — | — | US | claimed |
| EP-3162793-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | Amorepacific Corporation (KR) | 2017-05-03 | — | — | EP | claimed |
| CN-106660949-B | Chiral resolution method of N- [4- (1-aminoethyl) -phenyl ] -sulfamide derivative | 株式会社爱茉莉太平洋 | 2020-11-13 | — | — | CN | disclosed |
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | AMOREPACIFIC CORPORATION (KR) | 2019-11-19 | — | — | US | disclosed |
| EP-3162793-B1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORP (KR) | 2019-04-10 | — | — | EP | disclosed |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2017-11-30 | — | — | US | disclosed |
| EP-3162793-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | Amorepacific Corporation (KR) | 2017-05-03 | — | — | EP | disclosed |
| EP-2054411-B1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2014-08-20 | — | — | EP | disclosed |
| US-7858621-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-12-28 | — | — | US | disclosed |
| EP-2054411-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2009-05-06 | — | — | EP | disclosed |
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-12-18 | — | — | US | disclosed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | KDM4E 4638/4885ALDH1A1 797/4885GAA 3479/4885 |
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | DHCR24, SRR, ACMSD | KDM4E 2310/4885ALDH1A1 1008/4885GAA 2100/4885 |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | DHCR24, SRR, ACMSD | KDM4E 2310/4885ALDH1A1 1008/4885GAA 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.